UiPath Inc is a software-infrastructure business based in the US. UiPath shares (PATH) are listed on the NYSE and all prices are listed in US Dollars. UiPath employs 2,863 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $49.99 |
|---|---|
| 52-week range | $47.20 - $90.00 |
| 50-day moving average | $54.41 |
| 200-day moving average | $64.78 |
| Wall St. target price | $71.45 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.40 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $49.99 from 2021-10-15
| 1 week (2021-10-08) | -2.71% |
|---|---|
| 1 month (2021-09-17) | -7.90% |
| 3 months (2021-07-16) | -15.79% |
| 6 months (2021-04-13) | N/A |
| 1 year (2020-10-13) | N/A |
|---|---|
| 2 years (2019-10-13) | N/A |
| 3 years (2018-10-13) | N/A |
| 5 years (2016-10-13) | N/A |
Valuing UiPath stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of UiPath's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
UiPath's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 74.1286. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into UiPath's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider UiPath's PEG ratio in relation to those of similar companies.
| Revenue TTM | $736.9 million |
|---|---|
| Gross profit TTM | $541.8 million |
| Return on assets TTM | -10.03% |
| Return on equity TTM | -30.04% |
| Profit margin | -52.14% |
| Book value | $3.70 |
| Market capitalisation | $25.7 billion |
TTM: trailing 12 months
There are currently 15.5 million UiPath shares held short by investors – that's known as UiPath's "short interest". This figure is 56.9% up from 9.9 million last month.
There are a few different ways that this level of interest in shorting UiPath shares can be evaluated.
UiPath's "short interest ratio" (SIR) is the quantity of UiPath shares currently shorted divided by the average quantity of UiPath shares traded daily (recently around 9.0 million). UiPath's SIR currently stands at 1.73. In other words for every 100,000 UiPath shares traded daily on the market, roughly 1730 shares are currently held short.
To gain some more context, you can compare UiPath's short interest ratio against those of similar companies.
However UiPath's short interest can also be evaluated against the total number of UiPath shares, or, against the total number of tradable UiPath shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case UiPath's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 UiPath shares in existence, roughly 30 shares are currently held short) or 0.0563% of the tradable shares (for every 100,000 tradable UiPath shares, roughly 56 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against UiPath.
Find out more about how you can short UiPath stock.
We're not expecting UiPath to pay a dividend over the next 12 months.
You may also wish to consider:
UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. It develops UiPath Studio, a platform designed for RPA developers looking to build complex process automations with built-in governance capabilities, such as robust debugging tools, application programming interface automation, wizards to automate desktop or web applications, leverage custom code, and to integrate machine learning models into production workflows. The company also offers UiPath Robots, which emulates human behavior to execute the processes built in UiPath Studio; and UiPath Orchestrator that tracks and logs robot activity, along with what people do in tandem to maintain strict compliance and governance through dashboards and visualization tools. In addition, it provides maintenance and support for its software, as well as professional services, such as training and implementation services to facilitate the adoption of its platform. UiPath Inc. was founded in 2005 and is headquartered in New York, New York.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.